Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.075 USD
1.42%
Market Closed
Updated:
Apr 29, 2024
Adaptimmune Therapeutics PLC
Net Income (Common)
|
Adaptimmune Therapeutics PLC
Net Income (Common) Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Net Income (Common)
-$113.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Net Income (Common)
-$151.1m
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Net Income (Common)
-$208.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Net Income (Common)
-$180.7m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Income (Common)
-£55.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Net Income (Common)
£33.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
See Also
What is Adaptimmune Therapeutics PLC's Net Income (Common)?
Net Income (Common)
-113.9m
USD
-113.9m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Net Income (Common) amounts to -113.9m USD.
What is Adaptimmune Therapeutics PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-4%
-4%
Over the last year, the Net Income (Common) growth was 31%. The average annual Net Income (Common) growth rates for Adaptimmune Therapeutics PLC have been 4% over the past three years , -4% over the past five years .
You don't have any saved screeners yet
